Back to all research

Sermorelin: A Scientific Overview

July 7, 2026

Sermorelin is among the oldest and best-characterized growth-hormone-releasing-hormone analogs. This overview summarizes what the published research reports, strictly within a laboratory-research context.

What Is Sermorelin?

Sermorelin is GHRH (1-29) — a synthetic peptide corresponding to the first 29 amino acids of human growth-hormone-releasing hormone, the portion regarded as the biologically active core. It is often called the “prototypical” GHRH analog. Unlike ghrelin-receptor secretagogues (such as ipamorelin), sermorelin acts on the hypothalamic-pituitary-somatotropic axis via the GHRH receptor.

Mechanisms Studied in Research

  • GHRH-receptor agonism. Sermorelin has been studied for its association with pituitary growth-hormone release.
  • Endocrine profile. Studies report GH increases comparable to native GHRH, with some work noting small accompanying changes in other pituitary hormones.

Clinical & Research History

Sermorelin has been used historically in the diagnosis and study of growth-hormone deficiency, including work in pediatric growth disorders. A branded pharmaceutical form was previously available and later discontinued in the United States. Research-grade sermorelin today is supplied for laboratory research, not as that former drug product.

The State of the Evidence

  • Well-characterized mechanism, historical clinical use. Sermorelin’s GH-releasing activity is well documented, but current research-grade material is not an approved product.
  • Regulatory status. The former branded product was discontinued; research-grade material is supplied for laboratory research use only.

Key Takeaways

  • Sermorelin is GHRH (1-29), acting via the GHRH receptor rather than the ghrelin pathway.
  • It has a documented history in growth-hormone-deficiency research and diagnosis.
  • Research-grade material is for laboratory research use only.

References

  • “Pharmacokinetics of GHRH(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects.” PMID 8329825.
  • “Bioactivity of growth hormone releasing hormone (1-29) analogues after SC injection in man.” PMID 2546126.
  • “Beyond the androgen receptor: the role of growth hormone secretagogues...” PMC7108996.

Research Use, Legal Status & Handling

Material supplied for research is intended for in-vitro laboratory research use only. It is not a dietary supplement, drug, cosmetic, or food. Where an approved pharmaceutical version of a compound exists, research-grade material is not that approved product and is not intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Researchers are solely responsible for compliance with all applicable federal, state, and local laws and regulations in their jurisdiction. Research peptides are generally stored lyophilized, protected from light and heat, with reconstitution and handling performed per standard laboratory protocols.

Disclaimer: This article is provided for educational and informational purposes only and summarizes published laboratory and, where noted, clinical research. It is not medical advice or a recommendation for any form of use. Research-grade material is intended strictly for in-vitro research use only — not for human or veterinary consumption. Always consult a qualified professional regarding health-related questions.